Page last updated: 2024-11-02

4-phenylbutyric acid and Maple Syrup Urine Disease

4-phenylbutyric acid has been researched along with Maple Syrup Urine Disease in 1 studies

4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.

Maple Syrup Urine Disease: An autosomal recessive inherited disorder with multiple forms of phenotypic expression, caused by a defect in the oxidative decarboxylation of branched-chain amino acids (AMINO ACIDS, BRANCHED-CHAIN). These metabolites accumulate in body fluids and render a maple syrup odor. The disease is divided into classic, intermediate, intermittent, and thiamine responsive subtypes. The classic form presents in the first week of life with ketoacidosis, hypoglycemia, emesis, neonatal seizures, and hypertonia. The intermediate and intermittent forms present in childhood or later with acute episodes of ataxia and vomiting. (From Adams et al., Principles of Neurology, 6th ed, p936)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zubarioglu, T1
Dede, E1
Cigdem, H1
Kiykim, E1
Cansever, MS1
Aktuglu-Zeybek, C1

Trials

1 trial available for 4-phenylbutyric acid and Maple Syrup Urine Disease

ArticleYear
Impact of sodium phenylbutyrate treatment in acute management of maple syrup urine disease attacks: a single-center experience.
    Journal of pediatric endocrinology & metabolism : JPEM, 2021, Jan-27, Volume: 34, Issue:1

    Topics: Antineoplastic Agents; Child; Child, Preschool; Disease Management; Female; Follow-Up Studies; Human

2021